Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
Location: United Kingdom, England, Cambridge
Total raised: $12.47M
Founded date: 2012
Investors 6
| Date | Name | Website |
| - | 24Haymarke... | 24haymarke... |
| - | Ranworth C... | ranworthca... |
| - | Spex Capit... | spexcapita... |
| - | Cambridge ... | cambridgea... |
| - | Parkwalk A... | parkwalkad... |
| 24.11.2020 | BGF Ventur... | bgf.co.uk |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 20.11.2020 | - | $4.32M | - |
| 23.05.2016 | - | $2.17M | - |
| 02.06.2014 | Series A | $3.85M | - |
| 12.12.2013 | Series A | $2.13M | - |
Mentions in press and media 12
| Date | Title | Description |
| 30.12.2024 | DefiniGEN – closes series B funding round | We are delighted to announce our investment in DefiniGEN as part of a Series B funding round. DefiniGEN is shaping the future of liver research and toxicology, through highly predictive in vitro modelling. London, 26th September 2024 – Park... |
| 20.11.2020 | DefiniGEN secures £3.25 million in funding to fast-track growth | DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortiu... |
| 20.11.2020 | DefiniGEN secures £3.25m in funding led by BGF | - |
| 20.11.2020 | DefiniGEN secures £3.25 million in funding to fast-track growth | DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortiu... |
| 20.11.2020 | DefiniGEN secures £3.25 million in funding to fast-track growth | DefiniGEN secures £3.25 million in funding to fast-track growth 20-11-2020 DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 millio... |
| 23.05.2016 | DefiniGEN raises £1.5M in follow-on funding | DefiniGEN raises £1.5M in follow-on funding 23-05-2016 DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The investment will be used to fund the commercia... |
| 23.05.2016 | DefiniGEN raises £1.5M in follow-on funding | DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The investment will be used to fund the commercial launch of new pancreatic and lung stem cell products ... |
| 02.06.2014 | DefiniGEN announces closing of £2.3 million Series A fundraising | DefiniGEN announces closing of £2.3 million Series A fundraising 02-06-2014 DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced the final closing of its Series A funding round. The latest £1 mi... |
| 02.06.2014 | DefiniGEN announces closing of £2.3 million Series A fundraising | DefiniGEN Ltd, a leading provider of stem cell life science products and services, today announced the final closing of its Series A funding round. The latest £1 million ($1.6 million) placement for ordinary shares brings to a close a cumul... |
| 02.06.2014 | DefiniGEN Closes $3.83M Series A Funding | DefiniGEN, a Cambridge, United Kingdom-based provider of stem cell life science products and services, closed a $3.83m Series A funding round. The round was led by Cambridge Enterprise and 24 Haymarket, with participation from existing inve... |
Show more